HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials.

AbstractBACKGROUND & AIMS:
The efficacy of homocysteine-lowering therapy with folic acid to lower homocysteine levels in an effort to reduce cardiovascular disease (CVD) risk in patients with kidney disease remains inconclusive. We conducted a meta-analysis of relevant randomized trials to further examine this issue.
METHODS:
This meta-analysis included 8234 patients with kidney disease from nine qualified randomized trials using folic acid therapy, and with CVD reported as one of the endpoints. Relative risk (RR) was used to measure the effect of folic acid supplementation on risk of CVD using a random effects model.
RESULTS:
When pooling the nine randomized trials, folic acid therapy reduced the risk of CVD by 10%(RR = 0.90; 95% CI:0.81-1.00, P = 0.046). A greater beneficial effect was observed among those trials without a history of grain fortification with folic acid (0.82; 0.70-0.96, P = 0.01), with lower percent baseline diabetes (<30% (median), 0.80; 0.65-0.99, P = 0.04), and in patients with end-stage renal disease (ESRD) or advanced chronic kidney disease (ACKD) (0.85; 0.77-0.94, P = 0.002). Furthermore, a meta-regression analysis suggested a positive dose-response relationship between percent baseline diabetes and log-RR for CVD risk associated with folic acid supplementation (P = 0.007). Most importantly, even the inclusion of three subgroup results did not substantially affect the results (n = 11032, RR: 0.93; 95% CI:0.87-0.99, P = 0.03).
CONCLUSIONS:
Our meta-analysis indicates that folic acid supplementation may be effective for CVD prevention in patients with kidney disease, particularly in trials among patients without a history of grain fortification with folic acid, with lower percent baseline diabetes, and in patients with ESRD or ACKD.
AuthorsXianhui Qin, Yong Huo, Di Xie, Fanfan Hou, Xiping Xu, Xiaobin Wang
JournalClinical nutrition (Edinburgh, Scotland) (Clin Nutr) Vol. 32 Issue 5 Pg. 722-7 (Oct 2013) ISSN: 1532-1983 [Electronic] England
PMID23313356 (Publication Type: Journal Article, Meta-Analysis)
CopyrightCopyright © 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Chemical References
  • Folic Acid
Topics
  • Cardiovascular Diseases (epidemiology, etiology, prevention & control)
  • Dietary Supplements
  • Folic Acid (administration & dosage, therapeutic use)
  • Humans
  • Hyperhomocysteinemia (etiology, prevention & control)
  • Kidney Diseases (blood, diet therapy, physiopathology)
  • Kidney Failure, Chronic (blood, diet therapy, physiopathology)
  • Randomized Controlled Trials as Topic
  • Renal Insufficiency, Chronic (blood, diet therapy, physiopathology)
  • Risk
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: